New Dallas biotech firm the result of unique public-private partnership

September 16, 2003

DALLAS - Sept. 16, 2003 - Research pioneered at UT Southwestern Medical Center at Dallas has led to the formation of Reata Discovery Inc., a Dallas biopharmaceutical company with $5.2 million in start-up financing and statewide and international business partnerships.

Reata, created by an unusual public-private partnership, is different in that its drugs in development are further along in the Food and Drug Administration's approval process than most start-up firms' compounds, and it possesses platform technologies aimed at discovering news drugs to treat both cancer and neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. In contrast, most biotechnology startups stake their survival on one discovery or technology. Two of Reata's lead compounds are positioned to enter human testing in 2004.

"This is exciting news for UT Southwestern, but it's more exciting for the city of Dallas and the biotech industry in Dallas-Fort Worth," said Dr. Dennis K. Stone, vice president for technology development at UT Southwestern.

The public-private partnership is the result of a three-year effort by many individuals to assemble top-tier technologies into a company that is both broad and focused - broad in the sense that there are seven sets of technologies, each of which could be an entity unto itself; focused in that the technologies can be advanced through a single management platform, Dr. Stone said.

Discoveries from UT Southwestern, as well as partnerships with UT M.D. Anderson Cancer Center in Houston and several Asian companies, are at the heart of the company's technologies.

"Reata is the result of a lot of work by individuals committed to developing world-class therapeutics in Texas," Warren Huff, chief executive officer, said. "In Reata, we have combined clinical candidates, drug discovery platforms and the support of renowned scientists from leading Texas research institutions. Few Texas-based biotechnology companies have been formed to exploit this deep base of biological innovation."

Reata's founding scientists include: Dr. Jef Karel DeBrabander, assistant professor of biochemistry at UT Southwestern; Dr. Jonathan M. Graff, associate professor in the Center for Developmental Biology and of molecular biology at UT Southwestern; Dr. Waldemar Priebe, professor of medicinal chemistry at UT M.D. Anderson; Dr. Thomas Südhof, professor of molecular genetics and director of the Center for Basic Neuroscience at UT Southwestern; Dr. Philip J. Thomas, associate professor of physiology at UT Southwestern; and Dr. Jerry W. Shay, professor of cell biology at UT Southwestern.

Reata is developing four new classes of low molecular weight compounds discovered by its founding scientists. Each addresses a major unmet clinical need. And, while the Reata compounds include a mix of conventional and novel mechanisms of action, Reata has focused only on compounds that are highly specific and potent for a known target. In this way, Reata's lead projects have avoided the high cost and long process of obtaining compounds to test in advanced in vivo models and toxicology studies.

Reata also features a unique small-molecule discovery program focused on identifying new drugs useful in the treatment of neurological diseases, including Alzheimer's and Parkinson's. These diseases are now believed to be caused by a specific subset of toxic, improperly folded proteins. Although protein misfolding is now a topic of great interest in the research community, drug discovery efforts based on this insight have suffered from a lack of relevant assays. Reata founders have discovered a novel, proprietary assay technology that enables the efficient discovery of small-molecule drugs that rescue the critical proteins from misfolding.

The company will be based in Dallas, but the M.D. Anderson Cancer Center in Houston plays a very important part in the company's program, Dr. Stone said. Cooperation between scientists, clinicians and administrators at the two institutes to advance these technologies is another distinguishing characteristic of the company. In addition, Reata has a partnership in place with ScinoPharm of Taiwan and cooperation with Asian institutions to execute the chemical processes needed to manufacture and further develop the drug compounds.

Reata's Series A financing of $1.6 million was led by STARTech Early Ventures, a Texas-based business accelerator focused on assisting early-stage technology companies, including life science startups. Its Series B financing of $3.6 million was led by Ojai-Goliad partners James Bass and Peter Moody Brooks.

"The STARTech team, the founding scientists, Warren Huff, James Bass, Peter Brooks and the Office for Technology Development at UT Southwestern have worked shoulder-to-shoulder to create a company that emerges with highly advanced technologies, proven management and sophisticated investors who have provided substantial financing," Dr. Stone said.
To automatically receive news releases from UT Southwestern via e-mail, subscribe at

UT Southwestern Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to